UTHR UNITED THERAPEUTICS Corp

NEUTRAL Impact: 3/10 Insider Cluster (3 insiders)
Horizon days Filed May 26, 2026 Processed 10d 3h ago
Insider cluster: 3 insiders, $0.1M total

Price Chart

Loading chart...

Executive Summary

Three top insiders at United Therapeutics (CEO, CFO, General Counsel) sold a combined ~$110K in open-market transactions over two days. The dollar amount is trivial relative to the company's $24.1B market cap (~0.0005%) and is consistent with routine stock-for-tax settlements after option exercises. The cluster pattern is weak — these are small, liquidity-driven sales, not a coordinated signal of deteriorating fundamentals.

Key Financial Metrics

Direction
selling
Total Value
$110.0K
Insiders
3

Actionable Insight

Traders should treat this as routine and non-informative. The sales represent a tiny fraction of each executive's holdings and are paired with option exercises, suggesting tax- or diversification-driven dispositions. No bearish signal from this cluster. Monitor next quarterly filing for any shift in business momentum, but this insider activity alone does not warrant action.

Key Facts

  • CEO Martine Rothblatt sold 47 shares for $26K on May 22 (open-market).
  • CFO James Edgemond sold 40 shares for $22K on May 21 (open-market).
  • General Counsel Paul Mahon sold 110 shares for $61K on May 21 (open-market).
  • All three also exercised non-cash stock options or derivative conversions in the same window.
  • Total open-market sales = ~$110K, or 0.0005% of the $24.1B market cap.
  • No insider open-market purchases were reported in the cluster.

Financial Impact

Approximately $110,000 in insider sales — immaterial relative to $24.1B market cap.

no material impact on fundamentals

Risk Factors

  • Insider sales are small and likely liquidity-driven, but any unexpected acceleration in selling volume or pattern change in future filings would warrant closer scrutiny.
  • The company has no current known catalysts or disclosures that would explain insider selling — absence of red flags is not a guarantee of continued stock performance.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (22 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1779828428370
49 reports for UTHR
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+60▲ +5.53%Feb 25, 2026
Filters
Rows
Reports for UTHR — sortable, filterable
Type Now
Jun 5, 2026
today
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
Jun 4, 2026
1d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+20
Jun 4, 2026
1d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
Jun 3, 2026
2d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
May 29, 2026
7d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
May 28, 2026
8d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+20
May 27, 2026
9d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
May 26, 2026
10d ago
Insider Cluster
NEUTRAL ★ 3/10
awaiting T+20
May 26, 2026
10d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
May 22, 2026
14d ago
Insider Cluster
NEUTRAL ★ 2/10
awaiting T+20
Showing 10 of 49

US Market Status

Market Closed — Opens Mon (36h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access